Drug Search Results
More Filters [+]

Pyrazinamide

Alternative Names: pyrazinamide, rifafour, pyrazinamid, rifater
Latest Update: 2024-05-21
Latest Update Note: Clinical Trial Update

Product Description

Pyrazinamide (PZA) is a unique antituberculosis (anti-TB) drug that plays a key role in shortening TB therapy. PZA kills nonreplicating persisters that other TB drugs fail to kill, which makes it an essential drug for inclusion in any drug combinations for treating drug-susceptible and drug-resistant TB such as multidrug-resistant TB. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26104205/)

Mechanisms of Action: Fatty Acid Synthesis Inhibitor,Fatty Acid Synthetase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hongqi Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pyrazinamide

Countries in Clinic: Georgia, India, Kazakhstan, Korea, Pakistan, Peru, South Africa, Unknown Location

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary

Phase 2: Coinfection|HIV Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PARADIGM4TB

P2

Recruiting

Tuberculosis, Pulmonary

2027-02-24

METHOD

P2

Recruiting

Coinfection|HIV Infections|Tuberculosis, Pulmonary

2025-11-01

Hi-DoRi-3

P3

Not yet recruiting

Tuberculosis, Pulmonary

2025-08-01

endTB

P3

Completed

Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary

2023-06-01

Recent News Events